AbbVie shares new Vraylar real-world and pediatric data

On 19 September 2026, AbbVie presented new real-world and pediatric safety data for Vraylar at Psych Congress 2026. The findings evaluate the treatment in major depressive disorder and bipolar I disorder.

The real-world results evaluated routine clinical practice, covering patients with complex comorbidities and underserved populations. They demonstrated improvements in functioning and quality of life. The pediatric data provided details on long-term safety and use in younger patients suffering from mood disorders.

AbbVie, which holds a market capitalization of 466.6 billion dollars, views its neuroscience segment as an important driver for revenue stability and diversification away from older blockbuster drugs. The market will monitor how this evidence influences prescriptions and label adoption through 2027, especially for newly approved low-dose Vraylar in pediatric and adjunctive major depressive disorder settings.